[Targeted therapies in digestive oncology]

S Boutayeb; Y Bensouda; Z Fadoulkhair; K Bakkraoui; M Bachouchi; H Errihani

doi:10.1016/j.patbio.2012.05.013

[Targeted therapies in digestive oncology]

Pathol Biol (Paris). 2012 Aug;60(4):264-8. doi: 10.1016/j.patbio.2012.05.013. Epub 2012 Jun 26.

[Article in French]

Authors

S Boutayeb¹, Y Bensouda, Z Fadoulkhair, K Bakkraoui, M Bachouchi, H Errihani

Affiliation

¹ Service d'oncologie médicale, institut national d'oncologie, CHU Ibn Sina, Rabat, Maroc. boutayebdr@yahoo.fr

PMID: 22743093
DOI: 10.1016/j.patbio.2012.05.013

Abstract

Targeted therapies have an increasing importance in digestive oncology. These new treatments have been authorized in colon cancer, gastric cancer, pancreatic cancer, endocrine cancer and gastrointestinal stromal tumors. The oncologist should develop high abilities to use these therapies especially concerning the indications, response's biomarkers, toxicities and evaluation methods.

Publication types

Review

MeSH terms

Angiogenesis Inhibitors / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Antibodies, Monoclonal, Humanized / toxicity
Antineoplastic Agents / therapeutic use*
Colorectal Neoplasms / drug therapy
Digestive System Neoplasms / drug therapy*
ErbB Receptors / antagonists & inhibitors*
Gastrointestinal Stromal Tumors / drug therapy
Humans
Liver Neoplasms / drug therapy
Molecular Targeted Therapy*
Pancreatic Neoplasms / drug therapy
Stomach Neoplasms / drug therapy

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
ErbB Receptors